KADCYLA i.v. subst sèche 160 mg flac

7680628920022 CH-62892 L01FD03 07.16.1.

Active substances:

KADCYLA i.v. subst sèche 160 mg flac
KADCYLA i.v. subst sèche 160 mg flac
KADCYLA i.v. subst sèche 160 mg flac
1 / 3
google

Details

Product number
6289202
CPT
-
Packaging group
1
Unit
Durchstechflasche(n)
Composition
Praeparatio cryodesiccata: trastuzumabum emtansinum 160 mg, saccharum, acidum succinicum, natrii hydroxidum corresp. natrium 2.07 mg, polysorbatum 20, pro vitro.

Articles (1)

Kadcyla 160 mg, Pulver zur Herstellung eines Infusionslösungskonzentrates
Pulver zur Herstellung eines Infusionslösungskonzentrates
1
View

Official Swissmedic V2 data

Additional information from the official database

Official medical documents

Professional SmPC
Allemand
27/06/2025
Professional SmPC
Français
27/06/2025
Professional SmPC
Italien
27/06/2025

Detailed composition

Substance Quantity Type Category
trastuzumabum emtansinum
160.0 MG Substance Wirkstoff (Principe actif)
saccharum
- Substance HNIDK
acidum succinicum
- Substance HNIDK
natrii hydroxidum
- Substance HNIDK
natrium
2.07 MG Substance HBESI
polysorbatum 20
- Substance HNIDK

Reimbursement information

Public price
CHF 2618.50
Specialties list
Yes
Generic
No

Reimbursement limitation

SL addition date: 01/01/2016

Authorization holder

Roche Pharma (Schweiz) AG

4058 Basel

Authorization information

Swissmedic authorization number
62892
Drug name
Kadcyla, Pulver für ein Konzentrat zur Herstellung einer Infusionslösung
Galenic form
PULPI
ATC Code
L01FD03
Authorization status
Z
Dispensation category
A
First authorization
02/05/2013
Authorization expiration date
31/12/9999
IT number
07.16.1.
Domain
Human medicine
Field of application
Mammakarzinom

Packaging details

Description (FR)
KADCYLA i.v. subst sèche 160 mg flac
Description (DE)
KADCYLA i.v. Trockensub 160 mg Durchstf
Market launch
02/05/2013
Narcotic (BTM)
No

Other packaging sizes

KADCYLA i.v. subst sèche 100 mg flac
1 DUR
View
Buy us a coffee Explore the data